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Abstract
Vitamins are an essential part to wellbeing. This was not something always known however, as the Germ theory 
was the accepted thesis of the 18th century. It was found that certain accessory factors helped mitigate and even cure 
these diseases such as beriberi, scurvy, and rickets. Accessory factors, later coined vitamins by Casimir Funk, are an 
essential constituent of the human diet. Vitamin D is technically not a vitamin but functions as a steroid hormone 
whose most well-known purpose is calcification of the human skeleton. This helps prevent osteomalacia in adults 
and rickets, a serious problem in children due to their developmental stages. But besides its well-known role, vitamin 
D also has other important non-calcification purposes, including being a possible anticancer agent. Calcitriol (1,25 
dihydroxycholecalciferol, vitamin D3) has found to treat certain cancers in various ways: from the VDR-RXR complex 
to analogs being able to decrease tumor growth, lowering expression of stem cell marker genes, and inhibition of the 
Wnt pathway. Although there is promise in its effectiveness based on studies of squamous cell carcinoma, prostate, 
breast, colon, and ovarian cancer; hypercalcemia, lack of consistent data, and insufficient clinical trials are serious 
issues that constantly get in the way of progression of vitamin D’s legitimacy as a solution.
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At the beginning of the 18th century, scientists 
believed that a human was perfectly capable of being 
healthy based on only 4 necessary nutritional factors: 
proteins, carbohydrates, fats, and minerals. However, 
some diseases would severely affect human population 
at the time. Diseases such as beriberi, scurvy, pellagra, 
and rickets would baffle researchers as there weren’t 
any abnormal microorganisms found in the body at the 
time. The reason why these diseases were so difficult 
to understand was due to the accepted hypothesis of 
diseases at the time known as Germ theory. It states 
that any disease is due to some action or presence of a 
microorganism within the body [1]. Scientists later found 
out that these diseases were due to a lack of a specific 
component in the body [1]. According to Frederick 
Gowland Hopkins, states “no animal can live upon a 
mixture of pure protein, fat, and carbohydrate, even if 
necessary inorganic materials are supplied, an animal 
still can’t flourish” [2].
Historical background
During the Franco-Prussian war, the Siege of Paris 
occurred between 1870 and 1871 where several supplies 
for the French were cut off. Infant mortality rate was 
absurdly high during this period of time as there was a 
lack of milk. Experiments with rats conducted by Wilhelm 
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Stepp found that milk gave them normal growth; however, 
a milk substitute synthesized by opportunists (people 
who wanted to take advantage of the situation) failed to 
provide sustenance to the infants [3][4]. This lead to the 
conclusion that a lipid substance was found in milk which 
is essential to mice growth [5]. These accessory factors 
were found in very small amounts. These accessory 
factors, coined by Hopkins, were later termed vitamins by 
Casimir Funk in 1912, and were linked to solving vitamin 
deficient diseases [6][7]. Beriberi due to a lack of Vitamin 
B-1 (thiamin), Pellagra insufficient B-3 (niacin), scurvy 
insufficient Vitamin C, and rickets insufficient Vitamin 
D. Sir Edward Mellanby (1884-1955) was a researcher 
at King’s College for Women in London [8]. It was at this 
place in 1918-1919 that he discovered an accessory factor 
that played an essential part in preventing rickets. He fed 
puppies a diet that was found to produce rickets by giving 
them two different diets (Table 1). Milk was limited to less 
than 200 mL, if not, a rachitic diet would not be produced 
[9]. 
Table 1: Rachitic diets for the puppies. 
Rachitic Diets





Other puppies were given this nutrition with added 
foods into the diet, this was done to observe if some 
factor found in said foods could inhibit rickets (Table 2).





Meat Protein of meat
Watery extract of meat Casein
Malt extract Linseed oil
Commercial yeast extract 10g of yeast a day




It was concluded as there were some sort of accessory 
factors that prevents rickets and is fat-soluble as these 
were found in the extract of protein and fat [10]. This 
also showed that fats, proteins, and carbohydrates had 
no influence on the production of rickets, merely that 
rickets are a deficiency of a certain accessory factor. Later 
research my Mellanby and McCollum found out that the 
factor that prevents rickets and even cures them was a 
new vitamin termed Vitamin D [10].
Discussion
Vitamin D
Vitamin D (taken together) is technically not a vitamin. 
This is due to the fact that vitamins are substances that 
can’t be synthesized by our body and must be obtained by 
the foods we eat. Vitamin D, although it must be obtained 
from the environment, is mostly gathered from how long 
we are exposed to the sun as a typical diet won’t give 
sufficient amounts because of how little sources come 
from animals (the most common source being fatty fish 
such as tuna, salmon, or cod liver oil). Our geographic 
location and atmospheric pressure also explains why 
some regions of the world have people more susceptible 
to vitamin D deficiency diseases [11]. It’s important to 
note one can be Vitamin D deficient, but not be able 
to over consume Vitamin D from being exposed to UV 
radiation [12]. The only way an overdose could happen is 
due to excessive amounts of Vitamin D supplementation, 
which could be just as fatal as under consumption 
[12]. Vitamin D, however, is actually considered to be a 
steroid hormone. The active form of Vitamin D, known as 
Calcitriol (Figure 1), is a steroid hormone because it can 
regulate levels of calcium and phosphorus in our body. 
Calcitriol is capable of being synthesized within our body; 
this is done within our kidney and liver. Cholecalciferol, 
the inactive form of Vitamin D (Figure 1), is generated in 
our skin when UV radiation is absorbed by the precursor 
molecule, 7-dehydrocholesterol. Cholecalciferol is 
the supplement that can be found in stores where 
overconsumption can be toxic. This makes Vitamin D 
technically not a vitamin because they are unable to be 










Figure 1: Structures of Calcitriol and Cholecalciferol.
Pharmacokinetics
Human skin contains a sterol derivative known as 
7-dehydrocholesterol. Once this compound is exposed 
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to UV radiation it converts to the inactive form known as 
cholecalciferol (typically known as Pre-Vitamin D3) [12]. 
This cis-cis conformer is thermodynamically unfavorable 
and is energetic but is the only form that isomerizes 
to Vitamin D3. Vitamin D3 (or D2 if obtained from plants 
known as ergo sterol) is not biologically active however 
they still need to be converted to its physiologically active 
form, calcitriol [12]. First, cholecalciferol is hydroxylated 
(introduced a hydroxyl group) inside the liver where it 
becomes 25-hydroxy derivative of Vitamin D. This is done 
under the influence of the enzyme 25-hydroxylase. Next, 
it must be transported to the kidney where it again is 
hydroxylated, acting as a substrate for 1-alpha hydroxylase, 
where it is converted to 1,25-dihydroxycholecalciferol, 
the active form (Figure 2). It travels throughout the body 
via blood with its carrier protein, DBP (vitamin D-binding 
protein) [12]. Also, it’s worthy to mention that since it is 
difficult to lead a vitamin D fortified diet, it is possible 













Figure 2: Formation of Calcitriol from 
7-Dehydrocholesterol.
Calcification
Activated Vitamin D cannot play any ‘active’ role in 
human body without the Vitamin D receptor, a member 
of the nuclear receptor family whose purpose is allowing 
Calcitriol’s gene expression [14]. The most well-known 
function of Vitamin D is regulation of calcium in human 
body. This is monitored by the serum calcium levels in 
our blood, kidneys, and parathyroid hormone. If human 
serum calcium levels are found in low amounts, the 
parathyroid gland secretes a hormone, which responds 
to these levels (as well as phosphate) and secretes PTH 
(parathyroid hormone). This hormone then signals 
the kidney to begin producing activated Vitamin D and 
pulling calcium from our bones and into our circulatory 
system. This is done until the calcium levels have become 
balanced. This is all an example of our bodies’ excellent 
practice of homeostasis [15]. By this relatively simple 
function, it prevents disastrous effect that might occur 
in the body, including osteomalacia: a softening of the 
bones. There are a number of reasons why osteomalacia 
could occur, obviously from lacking Vitamin D; this could 
be due to not going out to get direct UV radiation or 
lacking from the diet. Although it was quite difficult to get 
Vitamin D from our diet, it is possible to irradiate many 
of our foods with Vitamin D and commonplace groceries, 
such as milk, have become Vitamin D fortified. There is 
debate however, about the effectiveness from fortified 
Vitamin D2 found in most foods as compared to D3 
obtained from the sun. Another reason for osteomalacia 
occurring could be due to kidney or liver problems, this 
can halt the mechanistic formation of Vitamin D in our 
body, and even if we do have a Vitamin D rich diet and are 
exposed daily to the sun, we will not be getting anything 
out of it since our body isn’t able to synthesize the active 
form. Osteomalacia in children is known as rickets and 
is considerably more severe as children’s bones are still 
forming. An example of the severity of rickets is bowed 
legs that are curved outward as well as other skeletal 
deformities [16]. Osteoporosis can also occur as a 
consequence of years of insufficient vitamin D thinning 
the bones and making them brittle. An insufficient 
calcium intake can prove dangerous for the elderly as a 
fall could prove a trip to the hospital over a broken hip 
[17]. Despite Vitamin D being most-well known for its role 
in bone formation, recent studies have shown that it also 
displays excellent noncalcemic functions. The reason is 
due to its Vitamin D receptor and analogs. 
Vitamin D receptor (VDR)
The Vitamin D receptor regulates many roles of 
vitamin D in human body due to its versatility. Calcitriol 
executes its functions only through this receptor. VDR 
has several binding domains for several occupants. The 
C-domain for binding to the DNA, E-domain for ligand-
binding, and an activating F-domain [18]. This means that 
VDR standardizes all the functions Vitamin D performs. 
This is excellent, however may create complications in 
preparation of its analogs and their functions. Regardless, 
this 427 amino acids’ constituted receptor works with 
Vitamin D-responsive elements (VDREs) found at the 
starting site of the specified gene. These VDREs’ 5’ arm 
attaches to the RXR, and its 3’ arm to the VDR [18]. This 
in turn heterodimerizes as well as acquiring an activator 
[18].
VDR possesses remarkable versatility. Interestingly, it’s 
found in many places including enterocytes, osteoblasts, 
and more recently discovered in parathyroid gland cells, 
keratinocytes, colon cells, and more [19]. Because VDR is 
present in these locations strongly suggests its functions 
are far beyond the scope of just bone formation. For 
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example, pioneering research by Suda et al. (2015) 
found that calcitriol can help terminally differentiate 
between promyelocytes and monocytes, precursors 
of the bone dissolving and absorption cell: osteoclasts. 
This demonstrates the importance in production of 
osteoclasts by use of Vitamin D [20]. As mentioned 
before, VDR is found in parathyroid gland cells, this has 
been found to be therapeutically useful in the treatment 
of renal osteodystrophy: a disease of the bones occurring 
due to kidneys being unable to regulate calcium and 
phosphorus levels in the blood. Treatments so far were 
mainly through the use of phosphorus retention, which 
in turn inhibited hyperphosphatemia [21]. This allowed 
serum calcium concentrations to return to regular levels 
[21]. Studies have also found that calcitriol (and analogs) 
also function to prevent parathyroid gland cells from 
rapidly multiplying. When the kidneys aren’t working 
as intended (renal failure), can affect circulation of 
calcium in the body, causing hyperproliferation of the 
parathyroid gland, secreting large amounts of parathyroid 
hormone, resulting in secondary hyperparathyroidism 
[22]. Regulation through calcitriol maintains healthy 
parathyroid glands in patients undergoing dialysis [22].
Vitamin D also has shown to have some therapeutic 
effect in treatment of certain autoimmune diseases such 
as multiple sclerosis and regulation of type 1 diabetes 
mellitus by increasing lag time, resulting in more time 
before diabetes actually occur [23][24]. Further studies 
are required to make firm conclusion.
Cancer and Vitamin D
It is well-known that calcitriol and VDR have increased 
utility and influence on the human body. It’s also worthy 
to restate that it can regulate gene expression, allowing 
influence to several signaling pathways involved in 
such processes like apoptosis and proliferation. This is 
especially seen when discussing Vitamin D’s impact on 
the following cytochrome P450 enzymes.
CYP27B1 and CYP24A1 
These renal enzymes are regulated by three hormones: 
calcitriol, fibroblast growth factor 23, and parathyroid 
hormone [25][26]. CYP27B1 is found in several extrarenal 
areas of interest. It’s also found in cancer cells, allowing 
it to impose anticancer influence [27]. Although CYP27B1 
is regulated by the hormones mentioned above, it’s only 
regulated as renal CYP27B1, their influence on extra renal 
CYP27B1 is nonexistent and cannot regulate its effects 
[27][28]. Synthesis of this enzyme depends on calcidiol 
substrate concentration. This indicates that Vitamin D 
could be a possible anticancer agent due to the inactive 
form easily being converted to calcitriol inside cancer 
cells [29][30]. This also means that since it is not under 
the influence of the 3 hormones, it can exert high levels 
of calcitriol concentration [31], but there is no question 
of hypercalcemia being a danger as of right now [27][28]
[32]. CYP24A1 is also found within cancer cells, yet serves 
no anticancer therapeutic effects, actually it suppresses 
calcitriol’s influence on them [33][34][35] classifying it 
as an oncogene (gene that may cause growth of cancer 
cells) [36]. Luckily, there are ways around this gene by 
use of cytochrome P450 inhibitors such as genistein 
[37], ketoconazole [38], and liarozole [39]. This in turn 
allows calcitriol’s influence to be prevalent once again. 
Unfortunately the use of these inhibitors enhances the 
calcemic effects of calcitriol, introducing hypercalcemia 
as a risk once more [40]. Caution must be taken when 
using these compounds in tandem. Furthermore, 
expression of CYP27B1 depends on the tumor, its 
progression, and targeted organ [29][30][41][42][43]. 
Regardless, this cytochrome metabolizing enzyme 
shows potential in being able to influence cancer-related 
pathways for treatment of it (information was obtained 
by performing studies on patients with breast, prostate, 
and other cancers) [44]. In a nutshell, calcitriol influences 
the activity of certain cytochrome metabolizing enzymes 
and subsequent interactions with various cancer cells. 
An outlined discussion is presented below considering 
the types of cancer based on organs and its promise as a 
future therapeutic agent.
Leukemia
An abnormality of the body’s bone marrow forming 
cancerous white blood cells, Leukemia is a cancer that 
affects less than 200,000 people in the United States per 
year [45]. Depending on its aggression, treatment may 
vary [46]. Calcitriol can regulate mineral metabolism in 
the body and can impose a differentiation inducing factor 
on this leukemic cell line (HL60), converting them into end 
cells (this means that it can transform a cancerous cell into 
a completely different cell) [47]. In vitro and in vivo tests 
were performed on patients who had preleukemia. In 
vitro study, calcitriol had a differentiating factor induced 
on the leukemic cells, but in vivo the results were not 
as well. Therapeutically speaking, it was virtually absent 
as it didn’t prevent 7 of the 18 patients from developing 
leukemia and 9 others developed hypercalcemia [47]. An 
analog that does not impose calcemic effects would be 
needed in order to make this therapy effective in patients 
suffering leukemia [47].
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Squamous cell carcinoma (SCC)
Often regarded as one of the most common skin 
cancers, squamous cell carcinoma usually affects the 
epidermal layers of the body. The reason as to why it’s 
much more common than leukemia (1 million diagnosed 
annually) could be due to too much exposure to UV 
radiation. Being exposed to the sun year-round and 
being a participant in tanning beds could proliferate 
abnormal cell growth to the exposed areas [48]. Calcitriol 
has the ability to change the expression of proteins that 
regulate the cell cycle in cancer cells resulting in the 
dephosphorylation of a retinoblastoma protein (function 
to suppress tumors and regulate cell cycle, doesn’t 
function in different cancers). Calcitriol also is known 
to down modulate a possible oncogene known as p21 
(WAF1/CIP1), an inhibitor thought to suppress tumors 
[49], but studies have shown that it prevents apoptosis 
and encourages rapid cancer cell growth. Finally, calcitriol 
also increases expression of p27Kip1, another cyclin-
dependent kinase inhibitor whose function is to slow down 
or even stop the cell cycle from proceeding. Calcitriol, 
along with help from dexamethasone, have shown to 
prevent SCC proliferation, and this is done by preventing 
cell cycle progression rather than programmed cell death 
[50] through apoptosis. This is therapeutically useful as 
studies were shown to be effective both in vitro and in 
vivo.
Prostate and Colon cancers
Prostate cancer is a very frequent cancer (males) 
worldwide. As many as 3 million men a year are diagnosed 
with prostate cancer although in most of the cases 
the rate of proliferation in prostate cancer is relatively 
slower than many other types of cancer. Treatment is 
simple if detected early and sometimes not necessary, 
however when it becomes metastatic, its aggression and 
advancement can be deadly [51]. Calcitriol demonstrated 
huge potential to fight against prostate cancer as found 
in vitro, however, with frequent uptake, the chance of 
hypercalcemia raises. EB1089, a synthetic analogue of 
Vitamin D (Figure 3), however might resolve this issue. It 
has the same anticancer effects that calcitriol would have 
on prostate cancer cells but does not induce a calcemic 
effect of any kind [52]. EB1089 and calcitriol were injected 
in various doses to 4 groups of male rats. Each group 
had 10 rats treated with MAT-Lylu cells (a cell line that 
induced proliferation of prostate tumor cells in male 
rats). There was also an extra group that served as the 
control, totaling 50 rats in 5 groups overall. The results 
were as expected: the control group had increased 
amount of tumor progression as compared to any of the 
4 experimental groups. The rats treated with calcitriol 
had tumor progression slowed, and with a higher dosage 
it also lowered the progression further, but with marked 
weight loss and development of hypercalcemia. On the 
other hand, rats with EB1089 showed tumor progression 
similar to that of calcitriol, without marked weight loss 
or hypercalcemia on either of the two groups [52]. There 
is much promise to be shown here and if possible how 
EB1089 could be incorporated to other cancers. This is 
truly the first successful synthetic analog that can be 
used for anticancer therapy. It is also worthy to note that 
EB1089 was able to successfully and effectively induce 
apoptosis of two carcinoma cell lines: SW620 and PC/JW 
[53]. This indicates that EB1089, along with possibly other 
synthetic analogues produced, could offer an alternative 









Figure 3: Structure of EB 1089.
Breast cancer
Breast cancer is known as the most commonly 
diagnosed cancer, being the 2nd most lethal type of 
cancer found in women. It initiates by the use of tumor-
initiating cells (also known as cancer stem cells) that 
creates cancer cells and continues to do so repeatedly 
at the site of the original tumor mass. The significance of 
this study was not necessarily if calcitriol or vitamin D as 
a dietary supplement could treat breast cancer, but how 
it does so. A mouse mammary tumor virus was induced 
in rats and later treated with calcitriol injections or a diet 
focused on vitamin D supplementation [54]. The results 
were not very exciting, but progressive toward support its 
push to therapeutic legitimacy. What was surprising was 
how effective calcitriol was when combined with ionizing 
radiation therapy, results far better than what either one 
could’ve done alone, creating a synergistic effect. The way 
it halted tumor progression was hypothesized to have 
been located at the Wnt/β-Catenin pathway [55]. This 
pathway is very important as it regulates stem cells that 
are considered pluripotent, meaning that it can create 
any kind of cell needed in the human body. 
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Ovarian cancer
Ovarian Cancer is a perplexing cancer for females. It’s 
undetectable in early stages, and symptoms usually don’t 
show up until it’s become advanced. There has been no 
real information on how to prevent ovarian cancer [56] 
although there are many instances that ovarian cancer 
functions the same way that breast cancer does via 
cancer stem cells. Interestingly, xenograft models of mice 
produced with ovarian cells from human, was shown that 
calcitriol therapy greatly slowed down tumor growth [57]. 
This was done by disrupting its cancer stem cells through 
the Wnt signaling pathway. The capacity to create its 
form under cultured conditions, the frequency of CSCs, 
was done in vivo by limited dilution analysis [57]. Much 
promise by seeing repeated paths or similar means of 
action by calcitriol indicates some form of consistency in 
its method of approach. 
Conclusion
In conclusion, vitamin D and its analogs demonstrated 
key role in regulating various diseases in human including 
cancer. The mechanism of action is not completely 
understood yet. Accordingly, further research is required 
to explore its therapeutic potential more appropriately 
for human wellbeing.
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